The U.S. FDA approved Bayer AG’s long-acting treatment for hemophilia A, a rare genetic disorder in which blood does not clot easily.

The EU’s CHMP adopted a positive opinion for Hemlibra (emicizumab) for routine prophylaxis of bleeding episodes in people with hemophilia A with factor VIII inhibitors.

At the American Society of Hematology meeting, Genentech revealed long-term data showing the drug maintains its efficacy over an extended period of time.

Roche’s emicizumab drug for treating hemophilia A showed positive interim results in a phase III study with children with inhibitors to clotting protein factor VIII.

Swiss-based Roche reported a death in its ACE910 study of emicizumab in patients with hemophilia A and factor VIII inhibitors.